Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

**Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score**

Ahmet Emre Eşkazan, İlker İnanç Balkan, Kaan Can Demirbaş, Muhlis Cem Ar, Ridvan Karaali, Yonca Sekibaş, Sait Mulamahmutoğlu, Güleren Yartış Dumanlı, Fatih Çakmak, Nurgül Özgür Yurtaş, Furkan Kurt, Seda Aladağ Kurt, Mert Kuşkucu, Seval Ürkmez, Şermin Börekçi, Devrim Sarıbal, Bilgül Mete, Işıl Bavunoğlu, Yalim Dikmen, Gökhan Aygün, Kenan Midilli, Fehmi Tabak

**Keywords:**
The Cerrahpaşa-PREDICT score, COVID-19, Cytokine release syndrome, Mortality, SARS-CoV-2, Tocilizumab

**A B S T R A C T**

Background: Cytokine release syndrome (CRS), characterized by overproduction of proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19), has been suggested as the major cause of mortality. Tocilizumab, a recombinant humanized monoclonal antibody against human IL-6 receptor, poses a therapeutic option for the treatment of CRS leading to severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection.

Methods: We performed a single-center retrospective study to reveal the outcome of COVID-19 patients on tocilizumab and proposed “the Cerrahpaşa-PREDICT score”, a new clinical scoring system using clinical and laboratory parameters that would help predicting the 28-day mortality of COVID-19 patients receiving tocilizumab.

Results: Eighty-seven patients (median age: 59 years) were included of whom 75.8% were male. Tocilizumab use significantly improved clinical and laboratory parameters. The 28-day mortality rate on tocilizumab was 16.1%. The Cerrahpaşa-PREDICT score, consisting of platelet counts, procalcitonin, D-dimer levels, SO2 and the time from symptom onset to tocilizumab administration had a positive predictive value of 94.5% and negative predictive value of 92.9% for anticipating 28-day mortality.

Conclusions: Severe COVID-19 should closely be monitored for the signs of hyperinflammation. We showed that administration of tocilizumab early in the course of the disease (prior to ICU admission) resulted in a favorable outcome. Close monitoring usually aids identifying patients who would benefit from tocilizumab. In this regard, the Cerrahpaşa-PREDICT score might serve as a practical tool for estimating the 28-day mortality in COVID-19 patients who received tocilizumab and would facilitate timely recognition of fatal cases to be evaluated for other therapeutic options.
1. Introduction

An outbreak of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has started in China in December 2019 and spread globally [1]. In about 80% of the cases, the disease presents with mild symptoms and has a good prognosis, while in the remaining 20%, it usually progresses to severe pneumonia and acute respiratory distress syndrome (ARDS), resulting in multiple organ failure (MOF) and death [2]. Cytokine release syndrome (CRS) caused by the overproduction of proinflammatory cytokines including interleukin (IL)-1 and IL-6 has been suggested to underlie the secondary hemophagocytic lymphohistiocytosis (sHLH) and the subsequent fatal lung involvement observed in severe COVID-19 [3-5].

IL-6 plays a central role in the pathogenesis of CRS, thus, blocking IL-6 receptors (IL-6Rs) might be beneficial and lifesaving in patients with COVID-19 experiencing CRS [6]. Tocilizumab (ACTEMRA®), a recombinant humanized monoclonal antibody against human IL-6R, has been included in the Turkish COVID-19 Management Guidelines as a therapeutic option for the treatment of severe SARS-CoV-2 infection [7,8].

There are studies published on the impact of tocilizumab use in COVID-19 [9-16], and we aimed to report our experience on tocilizumab therapy in this single-center retrospective study. Herewith, we also propose a new scoring system predicting 28-day mortality in COVID-19 patients receiving tocilizumab.

2. Methods

2.1. Patients

Adult patients with SARS-CoV-2 infection who received tocilizumab at Cerrahpaşa Faculty of Medicine between 16 March and May 01, 2020 were included. Diagnosis of COVID-19 was made on the basis of clinical, laboratory, and radiological findings and confirmed by the detection of SARS-CoV-2 RNA in oro-nasopharyngeal swab samples using reverse transcriptase – polymerase chain reaction (RT-PCR) [17,18]. In patients with initial RT-PCR negativity, sequential testing was performed especially in cases with typical clinical or radiological findings suggesting COVID-19.

The presenting signs and symptoms, vital signs and oxygen saturation on room air (SO2R), and laboratory results including complete blood count, C-reactive protein (CRP), procalcitonin, ferritin, lactate dehydrogenase (LDH), fibrinogen and D-dimer levels together with information on comorbidities and medications were obtained from patient files. Patients were classified as mild/moderate, severe, and critical as described by the WHO [2].

The study was approved by the local ethics committee for clinical trials (Date: April 21, 2020 and Number: 83045809-604.01.02) and the Review Board of the Turkish Ministry of Health.

2.2. Chest CT protocol

Chest computerized tomography (CT) scan was performed in all patients with risk factors or clinical evidence of pneumonia, unless contraindicated. All CT images were retrospectively reevaluated and scored using a revised CT scoring criteria [18] by a radiologist, who was blinded to the RT-PCR results and clinical status of the patients.

2.3. Initial COVID-19 treatment

Patients were managed according to the recommendations of Turkish Ministry of Health [8]. An initial treatment with hydroxychloroquine (± azithromycin) was given to all patients usually for 5–10 days depending on the clinical severity. A course of favipiravir for 5–10 days was added in high risk patients or in cases with progressive disease [8].

Evaluation of response to initial treatment and tocilizumab administration.

Patients with a progression to CRS despite antiviral treatment were considered as candidates for tocilizumab. Since IL-6 levels were not routinely measured, consecutive CRP measurements were used as a surrogate marker to trace the course of IL-6 levels. In patients showing clinical and laboratory deterioration with persistent fever and hypoxia despite hydroxychloroquine and favipiravir treatment 8 mg/kg of tocilizumab (max. per dose 400 mg) was administered intravenously in 100 mL saline over 60 min as recommended [8]. The same dose was repeated, if necessary, within 12–24 h, based on clinical and laboratory response. A rapid rise in CRP, ferritin and fibrinogen levels indicated the appropriate time for initiation of tocilizumab treatment.

2.4. Statistical analysis

All analyses were performed using IBM SPSS V.21. Mann-Whitney U test and paired samples T-test were used for the comparison of continuous variables where applicable. Chi-square test was used for comparing categorical variables. A p value less than 0.05 was considered statistically significant.

Uni- and multivariate regression were performed while inventing the proposed scoring system. Diagnostic significance of continuous clinical parameters was assessed by using receiver-operator characteristic (ROC) curve analysis. Youden’s J Index was calculated to identify optimal cut-off point for each parameter. To combine parameters which were found significant in univariate analysis according to the cut-off points, multivariate logistic regression analysis with forward variable selection approach was carried out. Due to high standard error estimates, Firth’s method was preferred to obtain coefficient estimations in multivariate logistic regression model [19-22]. For each variable that was statistically significant in the Firth’s model, a score was obtained, as described elsewhere [23]. ROC curve analysis was performed for probability, and the cut-off was determined. The accuracy of the prediction model was tested by calculating the area under the curve (AUC). In the calculator-development process, after logistic regression analysis, predicted probability was calculated for each patient by using the following formula: probability = exp(∑ β X)/(1+ exp(∑ β X)).

After applying logistic regression model, the estimated beta coefficients were used to assign score points. The beta coefficients in the model were multiplied by 10. Then, the value was rounded off to the nearest integer. After calculating the score, this variable was used to construct multivariate logistic regression model to obtain probabilities which were used as a combined diagnostic variable to assess diagnostic performance of the new score through ROC curve analysis. Finally, the AUC was calculated for the score. After obtaining the optimal cut-off point using Youden’s J Index the score was further evaluated in terms of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) associated with the 28-day survival following tocilizumab treatment.

3. Results

3.1. Baseline characteristics

Eighty-seven patients with a median age of 59 years (range, 24–92 years) were included in the study, constituting 10.6% (87/814) of all adult patients hospitalized for COVID-19 and 5.5% (87/1577) of those diagnosed with COVID-19 between 16 March and May 01, 2020 (Fig. 1). Patient characteristics on admission are displayed in Table 1. Hypertension was the most common comorbidity (31%), SARS-CoV-2 RNA was isolated from the oro-nasopharyngeal samples in 58 of the cases (66.7%). Median time from symptom onset to admission was 4 days (range, 1–15 days), and the median duration of hospitalization was 15 days (range, 6–36 days) (Table 1).

Coughing, dyspnea, fever, and myalgia were detected in 67 (77%), 48 (55.2%), 37 (42.5%), and 30 (34.5%) patients, respectively. Median
Table 1

| Characteristic                        | Patients (n = 87) |
|--------------------------------------|------------------|
| Age [years - median (range)]         | 59 (24–92)       |
| Sex [M/F – n (%)]                    | 66 (76)/21 (24)  |
| Comorbidities [n (%)]                |                  |
| Hypertension                         | 27 (31)          |
| Diabetes                             | 15 (17.2)        |
| Cancer                               | 10 (11.5)        |
| Chronic lung disease                 | 3 (3.4)          |
| None                                 | 28 (32.2)        |
| RT-PCR positivity [n (%)]            | 58 (66.7)        |
| Duration of symptoms prior to admission [days – median (range)] | 4 (1–15) |
| Initial signs/symptoms on admission [n (%)] |                  |
| Coughing                             | 67 (77)          |
| Shortness of breath                  | 48 (55.2)        |
| High fever                           | 37 (42.5)        |
| Myalgia                              | 30 (34.5)        |
| Headache                             | 8 (9.2)          |
| Diarrhea                             | 8 (9.2)          |
| Laboratory tests on admission [median (range)] |          |
| Neutrophil count [x 10^9/L]          | 4.3 (0.7–22.7)   |
| Lymphocyte count [x 10^9/L]          | 0.9 (0.3–6.1)    |
| Neutrophil/lymphocyte ratio          | 4.23 (0.77–30)   |
| Platelet count [x 10^12/L]           | 185.5 (34–418.7) |
| C-reactive protein [mg/L]            | 75 (1–396)       |
| D-dimer [mg/L]                       | 0.68 (0.19–6.14) |
| Ferritin [ng/mL]                     | 482 (71–2000)    |
| Fibrinogen [mg/dL]                   | 489 (173–875)    |
| Procalcitonin [mg/mL]                | 0.09 (0.03–2.11) |
| Lactate dehydrogenase [IU/L]         | 341 (145–1118)   |
| Alamine aminotransferase [IU/L]      | 25.5 (3–135)     |
| Creatinine [mg/dL]                   | 0.96 (0.44–8.48) |
| SO2R [%]                             | 94 (75–99)       |
| Types of oxygen therapy on admission [n (%)] |         |
| No oxygen support                    | 39 (43.5)        |
| Nasal cannula                        | 47 (54)          |
| Mask                                 | 3 (3.4)          |
| High-flow nasal therapy              | 2 (2.3)          |
| CPAP                                 | 1 (1.1)          |
| Intubation                           | 1 (1.1)          |
| Severity of disease [n (%)]          |                  |
| Mild/moderate                        | 26 (29.9)        |
| Severe                               | 58 (66.7)        |
| Critical                             | 3 (3.4)          |

a There were 4 cases with no data available.

b There were 44 patients with no ferritin result on admission.
c There were 48 patients with no data available.
d There was no data for one patient.

SO2R was 94% (range, 75%–99%). In 34 patients (39%), no oxygen support was needed, whereas the remaining 52 received various modes of oxygen therapy (Table 1). On admission, 29.9%, 66.7%, and 3.4% of the patients had mild/moderate, severe, and critical disease, respectively.

CT scoring was available for 86 patients (99%). Detailed information on the chest CT findings is given in Supplementary Fig. 1. Eighty-two patients (95.4%) had typical CT findings for COVID-19 pneumonia at diagnosis.

Median neutrophil and lymphocyte counts were 4.3 × 10^9/L and 0.9 × 10^9/L, respectively. Median platelet count was 185.5 × 10^9/L including 7 cases (8%) with a platelet count < 100 × 10^9/L. Median CRP, LDH, and D-dimer levels were 75 mg/dl, 341 IU/L, and 0.68 mg/L, respectively (Table 1).

Treatment for COVID-19 given prior to and/or during tocilizumab therapy were listed in Supplementary Fig. 2. All patients received hydroxychloroquine with a median of 10 days (range, 2–19 days), while 81 patients (93%) received favipiravir with a median of 5 days (range, 3–10 days) before and/or at the time of tocilizumab use.

Median durations from symptom onset and hospital admission to tocilizumab administration were 10 days (range, 3–24 days) and 6 days (range, 1–17 days), respectively. Seventy-five patients (86.2%) received tocilizumab in the COVID-19 wards, whereas in 12 cases (13.8%) tocilizumab was given in the ICU. Sixty-five patients (74.7%) received 2 doses of tocilizumab.

Comparison of baseline, tocilizumab administration, and post-tocilizumab Day 7 (D7) parameters.

Percentage of patients who needed oxygen support was significantly higher at tocilizumab use than on admission, and similarly percentage of patients free of oxygen support on D7 post-tocilizumab was significantly higher than that at tocilizumab administration (Supplementary Figure 3). On D7 of tocilizumab therapy, 63 patients were still in hospital, 20 had been discharged and 4 had died.

Table 2 summarizes the laboratory parameters on admission, at tocilizumab administration, and on D7 of tocilizumab. Median SO2R on admission was significantly higher than that at tocilizumab use, and this was 95% on D7 of tocilizumab, which was significantly higher than those observed on admission and at tocilizumb infuson (Table 2).

Neutrophil and platelet counts, and NLR on admission were significantly lower, but D-dimer levels were significantly higher than those at tocilizumab administration. On the contrary, lymphocyte counts were significantly lower, and the CRP and D-dimer levels were significantly higher at tocilizumab therapy when compared to levels on admission Table 2. Similarly, ferritin and LDH levels at tocilizumab administration were significantly higher than those on admission.

On D7 of tocilizumab, lymphocyte and platelet counts were significantly higher, whereas CRP, ferritin, and fibrinogen levels were significantly lower when compared to those at tocilizumab administration Table 2.

Lymphocyte and platelet counts were found significantly higher than baseline on D7 post-tocilizumab Table 2. CRP and fibrinogen levels were significantly lower, but D-dimer levels were significantly higher than those observed on admission (Table 2).

Out of the 13 patients who were intubated on D7 post-tocilizumab, eight (61.5%) died and 5 (38.5%) recovered during follow-up. Two additional patients were intubated after D7 of tocilizumab and died, making a total of 14 deaths (16.1%) within 28 days (Supplementary Fig. 4). Median durations from symptom onset and tocilizumab administration to death were 20.5 days (range, 10–31 days) and 9 days (range, 3–17 days), respectively. Of these 14 patients, 10 died due to secondary ventilator-associated pneumonia (VAP) accompanying ARDS, three died because of cardiovascular diseases and one patient with myelodysplastic syndrome died due to intracranial bleeding.
Counts and NLR were significantly higher at tocilizumab administration between survivors and non-survivors. In patients who died, neutrophil, lymphocyte, and LDH levels were significantly higher in patients who died compared to survivors. Patients who died were significantly older than those who survived (Table 2). A total of 24 parameters (age, sex, CT score, number of comorbidities, fever, shortness of breath, coughing, headache, myalgia, diarrhea, neutrophil, lymphocyte and platelet counts, NLR, CRP, D-dimer, ferritin, procalcitonin, LDH, ALT, AST, creatinine levels, and SO2R) were first tested in the univariate analysis. Eleven parameters were included procalcitonin but not CRP following variable selection to be significantly associated with survival (Table 4 A). In our score, we found to be significant (Table 4 A), and then a multivariate analysis was performed, which differentiated 5 parameters (platelet count, procalcitonin, SO2R, D-dimer, and time from symptom onset to tocilizumab use) to be significantly associated with survival (Table 4 B). In our score, we included procalcitonin but not CRP following variable selection methods, which was also supported by another study, in which

### Table 2

| Parameter on admission, at TCZ administration, and on the D7 of TCZ treatment. | Median (range) | On admission | At TCZ administration | Day 7 of TCZ treatment | p value |
|---|---|---|---|---|---|
| SO2R [%] | 94 (75–99) | 92.5 (73–99) | 95 (89–99) | 0.029<sup>a</sup> | 0.018<sup>b</sup> |
| Neutrophil count | 4.3 (0.7–22.7) | 5.1 (0.5–27.5) | 4.9 (0.3–27.2) | 0.012<sup>b</sup> | 0.045<sup>c</sup> |
| Lymphocyte count | 0.9 (0.3–6.1) | 0.9 (0.1–4.8) | 1.3 (0.3–5.9) | 0.016<sup>b</sup> | NS<sup>c</sup> |
| Neutrophil/lymphocyte ratio | 4.23 (0.77–30) | 5.12 (0.64–116) | 3.36 (0.3–52) | 0.01<sup>b</sup> | 0.032<sup>c</sup> |
| Platelet count | 185.5 (34–418.7) | 228 (21–541) | 361 (43–623) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| C-reactive protein | 75 (1–396) | 154 (4–399) | 4.9 (0.8–470) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| D-dimer | 0.68 (0.19–6.1) | 1.3 (0.26–80) | 2.4 (0.2–37) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| Ferritin | 482 (71–2000) | 801 (68–2447) | 644 (112–4666) | 0.014<sup>c</sup> | 0.004<sup>c</sup> |
| Fibrinogen | 489 (173–875) | 563 (163–900) | 259 (50–893) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| Procalcitonin | 0.09 (0.03–2.11) | 0.2 (0.03–4.65) | 0.05 (0.02–10.78) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| Lactate dehydrogenase | 341 (145–118) | 424 (191–1183) | 396 (183–1387) | <0.001<sup>b</sup> | <0.001<sup>c</sup> |
| Alanine aminotransferase | 25.5 (3–135) | 30 (4–232) | 82 (18–394) | <0.002<sup>b</sup> | <0.001<sup>c</sup> |
| Creatinine | 0.96 (0.44–8.48) | 0.9 (0.4–3.24) | 0.86 (0.56–3.09) | <0.001<sup>b</sup> | NS<sup>c</sup> |

<sup>a</sup> Represents the difference between the values at baseline and tocilizumab administration.

<sup>b</sup> Represents the difference between tocilizumab administration and post-TCZ D3 values.

<sup>c</sup> Represents the difference between the baseline and post-TCZ D7 values. (NS, not significant; TCZ, tocilizumab) (Paired sample T-test was used for these comparisons).

### Table 3

The comparison of parameters at the time of TCZ therapy between the surviving patients and the cases who died (Chi-square test is used for comparing the categorical variable and independent samples T-test (for normally distributed) and Mann-Whitney U test (for not normally distributed) were used for comparing continuous variables).

| Parameters at TCZ administration | Median (range) | Patients who survived | Patients who died | p value |
|---|---|---|---|---|
| Sex [M/F – n (%)] | 55/18 (75.3) | 11/3 (78.6) | NS | 0.001 |
| Age [years] | 58 (24–92) | 65.5 (43–83) | NS | 0.017 |
| Days from symptom start to TCZ therapy | 10 (4–24) | 12 (3–18) | NS | 0.017 |
| Percentages of patients receiving two doses of TCZ [%] | 72.6 | 71.4 | NS | 0.001 |
| Percentages of cases with ARDS [%] | 93 (73–99) | 89.5 (80–98) | 0.045 | 0.001 |
| Neutrophil count [x 10⁹/L] | 4.8 (0.5–15) | 8.8 (1.4–27.5) | NS | 0.019 |
| Lymphocyte count [x 10⁹/L] | 0.9 (0.2–4.8) | 0.8 (0.1–1.9) | NS | 0.015 |
| Neutrophil/lymphocyte ratio | 4.85 (0.81–70) | 10 (0.64–116) | NS | 0.015 |
| Platelet count [x 10⁹/L] | 237 (39–541) | 158 (21–341) | NS | 0.004 |
| C-reactive protein [mg/L] | 136 (4.0–239) | 202.5 | NS | 0.024 |

(Table 3). Although ferritin levels were higher in non-survivors than survivors, the difference was not statistically significant.

### 3.3. Safety of tocilizumab treatment

A moderate decrease in fibrinogen levels was detected on D7 following tocilizumab (Table 2). Seven patients had fibrinogen levels <100 mg/dL (median, 74 mg/dL – range, 50–99 mg/dL). Median alanine aminotransferase (ALT) level at tocilizumab administration was 30 IU/L, which was 82 IU/L on D7 of tocilizumab (Table 2). Elevation in ALT levels were observed in 42 cases (48.2%) within 7 days following tocilizumab administration, of which all returned to normal within 28 days of follow-up.

Of the 12 patients (14%) with secondary bacterial pneumonia (SBP) on D7 post-tocilizumab, 11 had VAP. Nine of those (75%) were diagnosed prior to tocilizumab administration. Three patients acquired SBP after tocilizumab.

### 3.4. The Cerrahpaşa-PREDICT (Procalcitonin, RESpiratory, D-dimer, Interval between onset of symptoms and tocilizumab, Thrombocyte) score

A total of 24 parameters (age, sex, CT score, number of comorbidities, fever, shortness of breath, coughing, headache, myalgia, diarrhea, neutrophil, lymphocyte and platelet counts, NLR, CRP, D-dimer, ferritin, fibrinogen, procalcitonin, LDH, ALT, AST, creatinine levels, and SO2R) were first tested in the univariate analysis. Eleven parameters were found to be significant (Table 4A), and then a multivariate analysis was performed, which differentiated 5 parameters (platelet count, procalcitonin, SO2R, D-dimer, and time from symptom onset to tocilizumab use) to be significantly associated with survival (Table 4B). In our score, we included procalcitonin but not CRP following variable selection methods, which was also supported by another study, in which
respectively. The AUCs for the calculation and the score were 0.942 (CI: 0.87–0.99) defined by the ROC curve analysis (Supplementary Figs. 5 and 6), and the cut-offs for the calculation (by the formula described in the methods section) and the score were 0.36585 and 62.5 (which was rounded off to the nearest integer).

In this retrospective cohort study, we analysed the clinical and laboratory characteristics of COVID-19 patients receiving tocilizumab to propose a scoring system for predicting the 28-day survival (the Cerrahpaşa-PREDICT score).

The median age was 59 years and most of the patients were male (76%), which was compatible with the literature [11,16]. On admission, fever, cough, and dyspnea were the most common symptoms, and the most common comorbidity was hypertension, as it was in most of the studies [10,11,15,25].

In our cohort, all patients received intravenous tocilizumab, whereas in some studies, tocilizumab was administered subcutaneously displaying similar efficacy [11]. Median duration from the onset of symptoms to tocilizumab use was 10 days, which was 12–13 days in other studies [12,15,26]. In line with the study by Morrison et al. [16], we showed that a duration of ≤12 days from symptom onset to tocilizumab use was an independent favorable factor predicting 28-day mortality.

Although it was shown that lower doses can also be efficient [10], although it was shown that lower doses can also be efficient [10], and then, the value was rounded off to the nearest integer.

### Table 4

| Parameter                      | Coef. | Std. Err. | p value | 95% CI       |
|-------------------------------|-------|-----------|---------|-------------|
| D-dimer                       | 2.502197 | 0.7386195 | 0.001   | 1.05453   |
| Platelet count                | 2.340325 | 0.6597936 | <0.001  | 1.047154 |
| Procalcitonin                 | 2.441678 | 0.8919675 | 0.006   | 0.6934535 |
| SO2R                          | 1.5058  | 0.5954439 | 0.011   | 0.3387519 |
| Time from symptom start to TCZ use | 1.17204 | 0.5843874 | 0.045   | 0.0266615 |
| Creatinine                    | 1.861573 | 0.6064267 | 0.002   | 0.6729981 |
| LDH                           | 2.017651 | 0.6607062 | 0.002   | 0.7226903 |
| Ferritin                      | 1.516689 | 0.5917773 | 0.01    | 0.3580024 |
| CRP                           | 1.908954 | 0.7316251 | 0.009   | 0.4749956 |
| INR                           | 1.892884 | 0.6585058 | 0.004   | 0.6021478 |
| Age                           | 1.612271 | 0.6166291 | 0.009   | 0.4043613 |

**A.** Parameters of the proposed score

**B.** Parameters of the proposed score

**C.** Parameters of the proposed score

### 4. Discussion

In this retrospective cohort study, we analysed the clinical and laboratory characteristics of COVID-19 patients receiving tocilizumab to propose a scoring system for predicting the 28-day survival (the Cerrahpaşa-PREDICT score).

The median age was 59 years and most of the patients were male (76%), which was compatible with the literature [11,16]. On admission, fever, cough, and dyspnea were the most common symptoms, and the most common comorbidity was hypertension, as it was in most of the studies [10,11,15,25].

In our cohort, all patients received intravenous tocilizumab, whereas in some studies, tocilizumab was administered subcutaneously displaying similar efficacy [11]. Median duration from the onset of symptoms to tocilizumab use was 10 days, which was 12–13 days in other studies [12,15,26]. In line with the study by Morrison et al. [16], we showed that a duration of ≤12 days from symptom onset to tocilizumab use was an independent favorable factor predicting 28-day mortality.

Although it was shown that lower doses can also be efficient [10], nearly three-quarter of patients received 2 doses (800 mg total) of tocilizumab as described before [16,27]. Following tocilizumab administration, the need for O2 therapy and SO2R values significantly improved, as displayed before [12,15,25,27]. Similarly, significant increases in lymphocyte and platelet counts after tocilizumab therapy were observed, which were compatible with previous studies [12,25]. Inflammatory parameters including CRP, ferritin, and fibrinogen levels significantly decreased following tocilizumab therapy as shown by Tonioni and colleagues [15].

Our study showed that administration of tocilizumab early in the course of the disease (prior to ICU admission) resulted in a favorable outcome with a 28-day mortality rate of 16.1%, similar to earlier reports with rates ranging between 16% and 25% [15,26,28]. On the contrary, a recently published placebo-controlled study showed that tocilizumab use did not prevent intubation or death among patients with severe COVID-19 [29]. Similarly, in another randomized placebo-controlled study, tocilizumab use did not demonstrate any significant benefit in hospitalized patients with severe COVID-19 pneumonia [30]. Clinical status and 28-day mortality rates were comparable between the tocilizumab and placebo arms. In our study, the 28-day mortality rate was 16.1%, which were 19.7% and 19.4% in the tocilizumab and placebo arms of the study by Rosas et al. respectively [30].

Our results were supported by more recently published two randomized controlled studies [31,32]. Among critically ill COVID-19 patients, tocilizumab treatment was shown to improve outcomes, including survival [31]. In the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial, enrolling more than 2000 patients in each arm, tocilizumab improved survival and clinical outcomes among hospitalized COVID-19 patients with hypoxia and CRS [32]. 28-day mortality was significantly higher in the control arm than that of patients receiving tocilizumab (33% vs. 29%, p = 0.0066).

In our cohort, surviving cases were significantly younger, confirming the prior observation that older age was a predictor of death [27]. CRP, LDH, and D-dimer levels were significantly lower in patients who survived, and platelet counts were significantly lower in cases who died. Similarly, Campochiaro and colleagues [28] showed that improving cases who died. Similarly, Campochiaro and colleagues [28] showed that improving patients had significantly lower CRP levels, while LDH levels did not
differ in their study. However, LDH levels were significantly higher in cases with clinical improvement in the study by Fernández-Ruiz et al. [33], and Quartuccio and colleagues [13] showed that patients receiving tocilizumab who required invasive ventilation had higher LDH levels than non-ventilated patients, which were compatible with our findings. Patients with D-dimer levels >3500 ng/mL were found to have inferior survival rates [14] and NLR was found significantly elevated in patients who died [34], all of which was in line with our results.

Elevation in ALT levels was observed in 48.2% of the cases, which was 44% in the cohort of Alattar et al. [9]. In our cohort, SBP rate was 14%, and it was 16% in one study [9] and bacterial infection rate was 21% in another [16]. In the recently published placebo-controlled studies [29,30], serious infection rates in the tocilizumab and placebo arms were 8.1% and 17.1% and 21% and 25.9%, respectively.

Herein we propose, “the Cerrahpaşa-PREDICT score”, for anticipating the 28-day mortality in COVID-19 patients receiving tocilizumab. This is an easy-to-use scoring system composed of 5 parameters including platelet count, procalcitonin, D-dimer levels, SO₂R and the time from symptom onset to tocilizumab use. FPV and NPV of the score were found to be 94.5% and 92.9%, respectively.

Our results should be considered with caution, due to the retrospective nature of our study. The study lacks a control arm, since tocilizumab was available from the first patient on at our center, who met the severity criteria according to the national guidelines. Other limitations include unavailability of viral load measurements and heterogeneity of the cohort, which consists of RT-PCR positive patients and clinically and radiologically proven RT-PCR negative cases and.

Moreover, determination of serum IL-6 levels before and after tocilizumab therapy would have been useful to demonstrate the immune modulating effect. However, in the absence of high-level clinical evidence to guide therapeutic interventions in such a rapidly growing pandemic, the wide off-label use of potentially beneficial agents is understandable. Our results including the proposed Cerrahpaşa-PREDICT score require further confirmation and validation through controlled prospective trials.

In conclusion, patients with severe COVID-19 should closely be monitored for the signs of hyperinflammation. Daily laboratory trends usually help identifying patients who would benefit from an anti-inflammatory intervention. In this regard, the Cerrahpaşa-PREDICT score might serve as a practical tool for estimating the 28-day mortality in COVID-19 patients, who received tocilizumab and would help recognising cases with negative outcome in order to early direct them to other therapeutic options.

4.1. Authorship statement

- AEE, İİB, MCA, RK, and FT developed the trial design and responsible for the organization and coordination of the trial.
- AEE and MCA are the chief investigators and responsible for the data analysis.
- KCD, YS, SM, GYD, FÇ, NÖY, FK, ŞB, SÜ, BM, İB, and YD collected data.
- SAK reevaluated the CT scans.
- MK, DS, GA, and KM performed the RT-PCR testings for the detection of SARS-CoV-2 RNA from the oropharyngeal and nasopharyngeal swab samples.
- All authors contributed to the writing of the final manuscript.
- All authors approved the final draft.

Declaration of competing interest

All authors have no conflict of interest to declare.

Acknowledgements

We wish to thank all the patients and their families, including the first case treated with tocilizumab who is a doctor and the mother of the first author of this paper. We are indebted to the healthcare personnel of Cerrahpaşa Faculty of Medicine Hospital and the management of Turkish Ministry of Health for punctually providing all free medication besides practice guidelines. We also thank Mr. İker Kürkçü for providing us statistical support. We dedicate this work to the memory of health care workers who have given their lives in the care of patients with COVID-19.

Appendix A. Supplementary data

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.jiac.2021.05.007](https://doi.org/10.1016/j.jiac.2021.05.007).

References

[1] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13.

[2] WHO. Clinical management of COVID-19. [cited 2020, June 2]; Available from:.

[3] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Mannion JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4.

[4] Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020;39(7):2085–9.

[5] Tufan A, Avanuoğlu Giller A, Matsucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing anti rheumatic drugs. Turk J Med Sci 2020;50(3):610–32.

[6] Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55(5):105954.

[7] Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55(5):105954.

[8] Turkey Ministry of Health. Anticytokin-anti-inflammatory therapies, management of coagulopathy. 2020 [cited 2020 June 3]; Available from: https://covid19bilgi.saglik.gov.tr/tr/covid19-eehberi.html.

[9] Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghlal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020;92(10):2042–9.

[10] Capra R, De Rossi N, Mattioli F, Romanelli G, Scarparizza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020;76:31–5.

[11] Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474–84.

[12] Morena V, Milazzo L, Orlev I, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med 2020;76:36–42.

[13] Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol 2020;129:104444.

[14] Sciancia S, Arafa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38(3):529–32.

[15] Toniati P, Piva S, Cattalin M, Garrafa E, Regola F, Cantelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19(7):102568.

[16] Morrison AR, Johnson JM, Grieve KM, Jones MC, Stine JJ, Hencken LN, et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. J Autoimmun 2020;111:102452.

[17] Wang X. Firth logistic regression for rare variant association tests. Front Genet 2014;5:187.

[18] Huang G, Gong T, Wang G, Wang J, Guo X, Cai E, et al. Timely diagnosis and management for the signs of hyperinflammation. Daily laboratory trends are usually helpful identifying patients who would benefit from an anti-inflammatory intervention. In this regard, the Cerrahpaşa-PREDICT score might serve as a practical tool for estimating the 28-day mortality in COVID-19 patients, who received tocilizumab and would help recognising cases with negative outcome in order to early direct them to other therapeutic options.

4.1. Authorship statement

- AEE, İİB, MCA, RK, and FT developed the trial design and responsible for the organization and coordination of the trial.
- AEE and MCA are the chief investigators and responsible for the data analysis.
- KCD, YS, SM, GYD, FÇ, NÖY, FK, ŞB, SÜ, BM, İB, and YD collected data.
- SAK reevaluated the CT scans.
- MK, DS, GA, and KM performed the RT-PCR testings for the detection of SARS-CoV-2 RNA from the oropharyngeal and nasopharyngeal swab samples.
- All authors contributed to the writing of the final manuscript.
- All authors approved the final draft.

Declaration of competing interest

All authors have no conflict of interest to declare.

Acknowledgements

We wish to thank all the patients and their families, including the
[23] Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum 2014;66(9):2613–20.

[24] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

[25] Xu X, Han M, Li T, Sun W, Wang B, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117(20):10970–5.

[26] Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020;50(5):397–400.

[27] Borku Uysal B, Ikitimur H, Yavuzer S, Ikitimur B, Uysal H, Islamoglu MS, et al. Tocilizumab challenge: a series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. J Med Virol 2020;92(11):2648–56.

[28] Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43–9.

[29] Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. BACC bay tocilizumab trial investigators. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med 2020;383(24):2333–44.

[30] Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med 2021;384(16):1503–16.

[31] REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med 2021;384(16):1491–502.

[32] RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637–45.

[33] Fernández-Ruiz M, López-Medrano F, Pérez-Jacinto Asín MA, Maestro de la Calle G, Bueno H, Caro-Teller JM, et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J Med Virol 2021;93(2):831–42.

[34] Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020;81(1):6–12.